Phenylalanine hydroxylase and Large neutral amino acid transporter 1 (PAH and LAT1)

The term "Endogenous phenylalanine-dependent enzymes and transporters" refers to the collective biological machinery responsible for the metabolism and systemic distribution of the essential amino acid phenylalanine. The primary components include phenylalanine hydroxylase (PAH), a hepatic enzyme that converts phenylalanine to tyrosine using the cofactor tetrahydrobiopterin (BH4), and the large neutral amino acid transporter 1 (LAT1/SLC7A5), which facilitates the movement of phenylalanine across the blood-brain barrier and into cells. Deficiencies in this system, particularly in PAH, lead to Phenylketonuria (PKU), a condition characterized by toxic phenylalanine accumulation that causes severe neurological damage. Therapeutic interventions either aim to restore the function of these endogenous proteins or bypass them entirely using non-human enzymes to maintain safe phenylalanine levels. Additionally, LAT1 is a significant target in oncology, as its inhibition can starve cancer cells of the amino acids required for rapid proliferation.

Other names

Endogenous phenylalanine-dependent enzymes and transportersPhenylalanine metabolism and transport systemPAH/LAT1 systemPhenylalanine-dependent metabolic pathway

Therapeutic strategies targeting this system include cofactor supplementation (e.g., sapropterin) to enhance endogenous PAH activity, enzyme substitution (e.g., pegvaliase) to degrade phenylalanine independently of the endogenous system, and competitive inhibition of transporters (e.g., JPH203) to block phenylalanine uptake into the brain or tumor cells.